| DRUG WATCH |
|
| Year : 2014 | Volume
: 46
| Issue : 1 | Page : 125-126 |
Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma
Mehmet A. N. Sendur1, Sercan Aksoy2, Nuriye Yildirim Özdemir1, Nurullah Zengin1
1 Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey
2 Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
Correspondence Address:
Mehmet A. N. Sendur
Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara
Turkey
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.125195
Bevacizumab is a recombinant humanized monoclonal antibody that selectively blocks the activity of vascular endothelial growth factor (VEGF) receptor and it is used in metastatic colorectal patients. We present here a case of fatal necrotizing fasciitis in a patient during bevacizumab treatment for colorectal cancer. In our review of the literature, necrotizing fasciitis was not reported before or during bevacizumab treatment.
[FULL TEXT] [PDF]*
|
